PPAP (1-Phenyl-2-propylaminopentane) — Safety, Research, Risks & Legal Status

Not medical advice. PPAP (1-Phenyl-2-propylaminopentane) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	α,N-Dipropylphenethylamine; DPPEA; MK-306; α-desmethyl-α,N-dipropylamphetamine
Category	Research Chemical
First described	1988, by József Knoll and colleagues (Hungary)
Drug class	Catecholaminergic Activity Enhancer (CAE); phenethylamine/amphetamine derivative
Development stage	Preclinical only; no human trials ever conducted or registered
Successor compound	BPAP (benzofuranylpropylaminopentane, 1999) - approximately 130x more potent via same mechanism
MAO inhibition	Absent - does not inhibit MAO, unlike parent compound selegiline
Regulatory status	Unscheduled in US; Schedule I Canada, Class A UK, scheduled Sweden 2020
US legal status	Not FDA-approved; classified as an experimental research chemical not approved for human use in the United States. Controlled as a Schedule I substance in Canada and as a Class A drug in the United Kingdom due to its structural classification as an amphetamine derivative. Scheduled in Sweden as of 2020. Has never been submitted to any regulatory agency for approval and has no legitimate pharmaceutical or dietary supplement status anywhere.

What is PPAP (1-Phenyl-2-propylaminopentane)?

PPAP (1-phenyl-2-propylaminopentane) is a synthetic phenethylamine and amphetamine derivative first described in 1988 by József Knoll and colleagues at a Hungarian research institution (later associated with Chinoin Private Co Ltd). It was developed as part of a program to characterize catecholaminergic activity enhancers (CAEs) - compounds capable of enhancing the release of catecholamine neurotransmitters in response to neuronal impulses. PPAP was derived structurally from selegiline (l-deprenyl) but lacks selegiline's MAO-inhibiting activity. It remains a preclinical research compound with no human trial history.

How it works

PPAP's primary characterized mechanism is enhancement of action potential-dependent (impulse-mediated) neurotransmitter release in catecholaminergic neurons - a profile termed Catecholaminergic Activity Enhancement (CAE). This is mechanistically distinct from MAO inhibition: unlike selegiline, PPAP does not inhibit monoamine oxidase. More recent in vitro evidence (2025) also classifies it as a catecholamine reuptake inhibitor, particularly for dopamine with lesser activity at norepinephrine transporters. The relative contribution of release enhancement versus reuptake inhibition to its observed behavioral effects in animals has not been fully resolved. All mechanistic characterization is from animal tissue and in vitro preparations.

Background & history

First described in 1988 by the Knoll laboratory in Hungary, with major pharmacological characterization published in the early 1990s - principally in the Journal of Neural Transmission and related journals. The compound was developed as part of a broader program exploring selegiline (l-deprenyl) derivatives for CNS activity. PPAP was notable for dissociating the CAE activity of selegiline from its MAO-inhibitory activity. Development interest effectively stalled by the late 1990s when the structurally distinct successor BPAP (introduced 1999) showed approximately 130x greater potency. PPAP has never entered any clinical development program and remains a strictly preclinical tool compound in the published literature.

What the research says

All available evidence is preclinical only; no human clinical trials have ever been conducted or registered for PPAP. Animal studies (primarily in rats) and in vitro brain tissue preparations demonstrated dose-dependent enhancement of impulse-mediated catecholamine release, including dopamine and norepinephrine, at nanomolar concentrations. Behavioral studies showed antagonism of tetrabenazine-induced motor suppression in rodents, consistent with a psychostimulant-like profile. More recent (2025) in vitro characterization identifies PPAP as a potent catecholamine reuptake inhibitor, particularly for dopamine. The bulk of published work was completed in the early 1990s; development interest shifted to the successor compound BPAP (benzofuranylpropylaminopentane, introduced 1999), which exhibits approximately 130-fold greater potency via the same proposed mechanism. No clinical development program has ever been initiated. ClinicalTrials.gov lists no registered trials for PPAP.

Reported effects

Enhanced dopamine and norepinephrine release in preclinical (animal/in vitro) models
Catecholamine reuptake inhibition identified in recent in vitro work
Antagonism of tetrabenazine-induced motor suppression in rodent behavioral assays
Psychostimulant-like activity profile in animal studies
No confirmed effects in humans - no human data exist

Dosing & administration (informational)

The published preclinical literature describes activity at nanomolar concentrations in in vitro brain tissue preparations and milligram-per-kilogram ranges in rodent behavioral studies. These values are animal and in vitro data only and cannot be extrapolated to human dosing - no pharmacokinetic, pharmacodynamic, or safety data in humans exist to support any dose estimate. No dosing information for human use is appropriate to provide. Anyone considering use for any medical purpose should consult a licensed clinician; this compound is not approved for any medical use.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No human safety data of any kind - compound has never been tested in humans
Preclinical animal work identified a psychostimulant-like activity profile, which carries inherent cardiovascular and CNS risk concerns by class analogy
No published toxicology, genotoxicity, or organ-toxicity studies identified in the literature
As an amphetamine derivative, theoretical risks include cardiovascular stress, abuse potential, and CNS stimulant adverse effects, though none have been formally characterized for PPAP
Absence of evidence of harm is not evidence of safety - the data gap is near-total for human exposure
Sourcing from research chemical markets introduces additional contamination and misidentification risks

Drug & supplement interactions

N
o
h
u
m
a
n
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
e
x
i
s
t
.
B
y
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l
c
l
a
s
s
a
n
a
l
o
g
y
(
d
o
p
a
m
i
n
e
a
n
d
n
o
r
e
p
i
n
e
p
h
r
i
n
e
r
e
u
p
t
a
k
e
i
n
h
i
b
i
t
i
o
n
p
l
u
s
c
a
t
e
c
h
o
l
a
m
i
n
e
r
e
l
e
a
s
e
e
n
h
a
n
c
e
m
e
n
t
)
,
t
h
e
o
r
e
t
i
c
a
l
i
n
t
e
r
a
c
t
i
o
n
r
i
s
k
s
i
n
c
l
u
d
e
:
s
e
r
o
t
o
n
e
r
g
i
c
a
g
e
n
t
s
(
r
i
s
k
o
f
s
e
r
o
t
o
n
i
n
s
y
n
d
r
o
m
e
)
,
o
t
h
e
r
s
t
i
m
u
l
a
n
t
s
o
r
s
y
m
p
a
t
h
o
m
i
m
e
t
i
c
s
(
a
d
d
i
t
i
v
e
c
a
r
d
i
o
v
a
s
c
u
l
a
r
a
n
d
C
N
S
e
f
f
e
c
t
s
)
,
M
A
O
i
n
h
i
b
i
t
o
r
s
(
p
o
t
e
n
t
i
a
l
l
y
s
e
v
e
r
e
h
y
p
e
r
t
e
n
s
i
v
e
o
r
s
e
r
o
t
o
n
e
r
g
i
c
r
e
a
c
t
i
o
n
s
)
,
a
n
d
a
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
m
e
d
i
c
a
t
i
o
n
s
(
a
n
t
a
g
o
n
i
s
m
o
f
e
f
f
e
c
t
)
.
T
h
e
s
e
a
r
e
c
l
a
s
s
-
l
e
v
e
l
i
n
f
e
r
e
n
c
e
s
,
n
o
t
c
o
m
p
o
u
n
d
-
s
p
e
c
i
f
i
c
d
a
t
a
.

Who should avoid it

Any MAO inhibitor (theoretical severe interaction risk by pharmacological class)
Other stimulants or sympathomimetic agents (additive cardiovascular risk)
Serotonergic drugs including SSRIs, SNRIs, triptans (serotonin syndrome risk by class analogy)
Cardiovascular or arrhythmia medications (unpredictable interaction in absence of any human PK/PD data)
Use by anyone with personal or family history of cardiovascular disease, psychosis, or stimulant sensitivity - no safety margin has been established

How it is commonly combined

No stacking data exist for PPAP in humans. Its use in any combination is entirely without evidence base. The preclinical literature studied it as a single agent. Combining a catecholamine reuptake inhibitor and releaser with other CNS-active compounds carries uncharacterized and potentially serious risks.

Legal & regulatory. Not FDA-approved; classified as an experimental research chemical not approved for human use in the United States. Controlled as a Schedule I substance in Canada and as a Class A drug in the United Kingdom due to its structural classification as an amphetamine derivative. Scheduled in Sweden as of 2020. Has never been submitted to any regulatory agency for approval and has no legitimate pharmaceutical or dietary supplement status anywhere.

Quality & harm reduction

N
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
o
r
r
e
g
u
l
a
t
e
d
s
u
p
p
l
y
e
x
i
s
t
s
.
P
P
A
P
h
a
s
n
o
a
p
p
r
o
v
e
d
m
a
n
u
f
a
c
t
u
r
i
n
g
s
t
a
n
d
a
r
d
s
,
n
o
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
r
e
q
u
i
r
e
m
e
n
t
s
u
n
d
e
r
a
n
y
r
e
g
u
l
a
t
o
r
y
f
r
a
m
e
w
o
r
k
,
a
n
d
n
o
c
o
m
p
o
u
n
d
i
n
g
p
h
a
r
m
a
c
y
s
t
a
t
u
s
.
A
n
y
m
a
t
e
r
i
a
l
a
v
a
i
l
a
b
l
e
o
u
t
s
i
d
e
a
l
i
c
e
n
s
e
d
r
e
s
e
a
r
c
h
s
e
t
t
i
n
g
i
s
u
n
v
e
r
i
f
i
e
d
r
e
s
e
a
r
c
h
c
h
e
m
i
c
a
l
s
t
o
c
k
w
i
t
h
n
o
g
u
a
r
a
n
t
e
e
d
p
u
r
i
t
y
,
p
o
t
e
n
c
y
,
o
r
i
d
e
n
t
i
t
y
.
I
n
d
e
p
e
n
d
e
n
t
t
h
i
r
d
-
p
a
r
t
y
a
n
a
l
y
t
i
c
a
l
t
e
s
t
i
n
g
(
H
P
L
C
,
N
M
R
,
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
)
w
o
u
l
d
b
e
t
h
e
m
i
n
i
m
u
m
b
a
r
f
o
r
a
n
y
l
e
g
i
t
i
m
a
t
e
l
a
b
o
r
a
t
o
r
y
u
s
e
.

Find PPAP (1-Phenyl-2-propylaminopentane) →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is PPAP related to selegiline (l-deprenyl)?

Yes, structurally. PPAP was derived from the deprenyl scaffold as part of a program to isolate its catecholamine-enhancing activity from its MAO-inhibitory activity. PPAP retains the catecholaminergic enhancer profile but does not inhibit MAO, which distinguishes it pharmacologically from selegiline.

Has PPAP ever been tested in humans?

No. All published data are from animal studies (primarily rats) and in vitro brain tissue preparations. No human pharmacokinetic, pharmacodynamic, safety, or efficacy data exist. No clinical trials have ever been registered on ClinicalTrials.gov or elsewhere.

What dose should I take?

No dosing guidance for human use exists or can be responsibly provided. PPAP has no approved human dose, no established safety margin, and no clinical trial history. Any use would constitute uninvestigated self-experimentation with an unapproved research chemical. Consult a licensed clinician for any medical question this may relate to.

Is PPAP legal in the United States?

PPAP is not explicitly scheduled under the federal Controlled Substances Act as of this writing, but it has no FDA-approved status, no supplement status, and no legitimate pathway for human use. It is a research chemical classified as not for human consumption. Structural analogue provisions and state-level scheduling may apply. In Canada, the UK, and Sweden it is already controlled. Legal status can change; verify current law before drawing conclusions.

Why was research on PPAP discontinued?

Development interest shifted to BPAP (benzofuranylpropylaminopentane), introduced in 1999, which was found to be approximately 130-fold more potent than PPAP at catecholamine and serotonin release enhancement while operating through the same general mechanism. PPAP itself never reached clinical development for any indication.

Is there a safer alternative for the underlying purpose PPAP is studied for?

The conditions that PPAP's mechanism is theorized to be relevant to - neurodegenerative disease, mood disorders, cognitive decline - have established clinical treatment pathways. Selegiline (l-deprenyl) is FDA-approved for Parkinson's disease and major depressive disorder and has a characterized human safety and efficacy profile. Any clinical need should be discussed with a neurologist or psychiatrist, not addressed with an uninvestigated research chemical.

References & further reading

PubMed: 1-phenyl-2-propylaminopentane PPAP deprenyl catecholaminergic activity enhancer Knoll
PubMed: pharmacology PPAP deprenyl-derived psychostimulant phenethylamine
PubMed: BPAP benzofuranylpropylaminopentane catecholamine serotonin release enhancer successor PPAP
ClinicalTrials.gov: PPAP 1-phenyl-2-propylaminopentane (no registered trials found as of 2025)
PubMed: selegiline deprenyl derivatives catecholaminergic activity enhancement Knoll 1990s